ASM Microbe 2018
ASM Microbe 2018
Thirteen AWG member companies presented data from their clinical and research programs at the American Society for Microbiology’s ASM Microbe 2018 meeting held June 7-11, 2018 in Atlanta, GA. Representatives from AWG member companies participated in 88 different presentations and oral sessions.
ASM Microbe showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology from basic science to translation and application.
Friday, June 8th
Session 012: New Agents Discovery Summary Session: Early New Antimicrobial Agents
Time: 8:45 a.m. – 10:45 a.m. ET
Location: A411 and Lounge and Learn 1, Building A, Level 4
Amplyx:
9:30 a.m. – 9:45 a.m.
- 8: APX001: A First-in-class, Broad Spectrum Antifungal Agent
Session 040: FRIDAY – CPHM Late-breakers
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
T2 Biosystems:
- FRIDAY – CPHM LB6: Clinical Performance of T2Bacteria among Patients with Bloodstream Infections Due to Five Common Bacterial Species
- FRIDAY – CPHM LB6: Clinical Performance of T2Bacteria among Patients with Bloodstream Infections Due to Five Common Bacterial Species
Session 042: CPHM02 – Antimicrobial Susceptibility Testing: Gram-Negative Bacteria
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- FRIDAY – 233: Comparative Evaluation of Meropenem/Vaborbactam Mic Determination with the New Etest® Mev* and Clsi 2017 Broth Microdilution Method
- FRIDAY – 234: Development of Meropenem-Vaborbactam Mic Assay for Gram Negative Bacteria on Microscan Dried Gram Negative Mic Panels
- FRIDAY – 238: A Multi-Site Study Comparing A Commercially Prepared Dried Mic Susceptibility Sys. to the Clsi/Iso Broth Microdilution Method for Fda Approved Delafloxacin (Baxdela) Using Gram-Negative Non-Fastidious Organisms
- FRIDAY – 240: Multi-Site Evaluation of Meropenem/Vaborbactam Mic Test Strip Compared to Broth Microdilution for Enterbacteriaceae and P. Aeruginosa
Session 048: FRIDAY – AAR Late-breakers
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Cidara Therapeutics:
- FRIDAY-AAR LB21 – Clinical Efficacy and Safety of Rezafungin (CD101): Results from STRIVE, a Randomized, Double-blind, Multicenter, Phase 2 Study in the Treatment of Candidemia and/or Invasive Candidiasis
Melinta Therapeutics:
- FRIDAY – AAR LB12: Advanced Pyrrolocytosine Leads are Potent in Vitro against Enterobacteriaceae Expressing the Plasmid-mediated Colistin-resistance Gene, mcr-1
- FRIDAY – AAR LB14: Advanced pyrrolocytosine leads are potent in vitro against the multiple resistance mechanisms present in the CDC Enterobacteriaceae Carbapenemase Diversity Panel
Session 049: AAR01 – Surveillance of AMR: Molecular Typing, Clinical & Molecular Epidemiology: Antimicrobial Surveillance Studies in HospitalsTime: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- FRIDAY – 395: Epidemiology and Outcomes of Carbapenem Resistance among Patients with Hospital-Acquired and Ventilator-Associated Pneumonia
- FRIDAY – 415: Microbiology of Culture-Positive Skin and Skin Structure Infection among Hospitalized Patients in the U.S., 2015-2017
Theravance Biopharma:
- FRIDAY – 416: Activity of Telavancin against A Contemporary Collection of Staphylococcus aureus Clinical Isolates from All Nine Us Census Bureau Divisions
Session 050: AAR01 – Surveillance of AMR: Molecular Typing, Clinical & Molecular Epidemiology: Molecular Typing and Evolution of Resistance in Staphylococci, Enterococci and Streptococci
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- FRIDAY – 452 – Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clin. Isolates
Session 054: AAR03 – Antifungal Agents and Resistance: Agents to Treat Fungal Infections
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Amplyx:
- FRIDAY – 488: Apx001 is Effective Treatment for Murine Coccidioidomycosis
Cidara Therapeutics:
- FRIDAY-485 – Activity of a Long-Acting Echinocandin Rezafungin (CD101) and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2016
- FRIDAY-496 – CD101 Exhibits Low Minimum Inhibitory and Mutant Prevention Concentrations against Candida glabrata Clinical Isolates
- FRIDAY-507 – Establishment of Quality Control Ranges for the Broth Microdilution Susceptibility Testing of Rezafungin against Yeast
SCYNEXIS:
- FRIDAY – 497: Morphological Effect of Scy-078 and Caspofungin on Different Echinocandin-Resistant Candida Species
- FRIDAY – 498: In Vitro Activity of Scy-078 in Combination with Isavuconazole Or Amphotericin B against Medically Important Moulds
- FRIDAY – 506 – Does Sabouraud Dextrose Broth, Compared to Rpmi, Differentiate Susceptibility between Resistant and Susceptible Candida Glabrata And C. Albicans Isolates to Scy-078, A Novel β-D-Glucan Synthase Inhibitor and Caspofungin?
Session 056: AAR04 – Antimicrobial PK/PD & General Pharmacology: In vitro Models
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Zavante Therapeutics:
- FRIDAY – 521: In Vitro Investigation of Synergy among Fosfomycin (Fos) and Various Antimicrobials against Carbapenemase-Producing Enterobacteriaceae (Cpe)
- FRIDAY – 522: In Vitro Synergy of Fosfomycin (Fos) and Parenteral Antimicrobials against Carbapenem-Nonsusceptible (Cp-Ns) Pseudomonas Aeruginosa (Psa)
Session 061 – AAR07 – Experimental Therapeutics: New Targets, Scaffolds, Combinations and Delivery Systems
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- FRIDAY – 566 – Pyrrolocytosines: A Completely New Class of Antibiotics with Potent Efficacy against Biothreat Pathogens
Session 067: CIV01 – Clinical Studies of Adult Infectious Diseases: Skin, Bone and Joint Infections
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- FRIDAY: 688 – Admission Rate and Length of Stay for Skin Infection Patients in Us Hospitals: Use of Oritavancin is Associated with Lower Rates of Hosp. Admission and Shorter Length of Stay
- FRIDAY – 689: Economics of Treatment of Skin and Soft Tissue Infections (Ssti) in Us Hospitals
Session 068: CIV01 – Clinical Studies of Adult Infectious Diseases: Urogenital Tract Infections
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Iterum Therapeutics:
- FRIDAY – 695: Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Outpatient Urinary Tract Infection Due to Fluoroquinolone Non-Susceptible Uropathogens
Session 150: PK/PD Optimized Antimicrobial Therapy
Time: 3:00 p.m. – 3:45 p.m. ET
Location: Lounge and Learn 2, Building A, Level 3
Spero Therapeutics:
3:10 p.m. – 3:15 p.m.
- 4: Potent Activity of A Novel Gyrase Inhibitor (Spr719/Spr720) In Vitro And in A Prolonged Acute Mycobacterium Abscessus Mouse Model of Infection
3:25 p.m. – 3:30 p.m.
- 7: Pharmacokinetics and Pharmacodynamics of Tebipenem for Multidrug Resistant Enterobacteriaceae
Saturday, June 9th
Session 205: Resistant Gram-negative Pathogens in the Hospital
Time: 11:00 a.m. – 12:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5, CIV Hub, Learn
Melinta Therapeutics:
11:40 a.m. – 11:50 a.m. ET
- 6 – Predicting Carbapenem Resistance among Gram-Negative Pathogens in Complicated Urinary Tract Infections
Session 218: SATURDAY – CPHM Late-breakers
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
T2 Biosystems:
- SATURDAY – CPHM LB6 – Evaluation of T2 Magnetic Resonance Candida auris Panel as a Rapid Diagnostic for this Emerging Multidrug Resistant Yeast in Clinical Skin-Swab Samples
Session 219: CPHM02 – Antimicrobial Susceptibility Testing: Gram-positive and Fastidious Bacteria
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- SATURDAY – 209: A Multi-Site Study Comparing A Commercially Prepared Dried Mic Susceptibility Sys. to the Clsi Broth Microdilution Method for Eravacycline Using Fastidious Organisms
Theravance Biopharma:
- SATURDAY – 215: Evaluation of Three Testing Methods for Telavancin Activity against S. Aureus with Reduced Susceptibility
- SATURDAY – 216: Performance of Etest Telavancin for Antimicrobial Susceptibility Testing of Staphylococcus aureus and Enterococcus faecalis
Session 220: CPHM03 – Diagnostic Bacteriology: Consider the Source
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
T2 Biosystems:
- SATURDAY – 237 – Evaluation of the T2bacteria Panel (T2bp) Compared to Standard Blood Culture At Ochsner Med. Center
Session 227: AAR01 – Surveillance of AMR: Molecular Typing, Clinical & Molecular Epidemiology: Community-associated Infections by Multidrug-Resistant Bacteria
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Nabriva Therapeutics:
- SATURDAY – 387: A Multicenter Evaluation of Pathogen Distribution in Patients Admitted with Microbiologically-Confirmed Community-Acquired Bacterial Pneumonia (Cabp) in the Us
Session 233: AAR04 – Antimicrobial PK/PD & General Pharmacology: in vivo Studies
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Nabriva Therapeutics:
- SATURDAY – 557: Tissue Distribution of [14C]-Lefamulin Into the Urogenital Tract in Rats
Melinta Therapeutics:
- SATURDAY – 549: In Vivo Activity of Solithromycin and Levofloxacin in A Murine Pneumonia Mixed-Infection Model Caused by Streptococcus Pneumoniae and Anaerobic Bacteria
Spero Therapeutics:
- SATURDAY – 555: Pharmacokinetics and Pharmacodynamics of Tebipenem for Multidrug Resistant Enterobacteriaceae
- SATURDAY – 561: Assessment of the In Vivo Efficacy of Spr741 in Combination with Azithromycin (Azm) against Multidrug (Mdr) Resistant Enterobacteriaceae (Eb) Isolates in the Neutropenic Murine Thigh Infection Model
Session 234: AAR05 – Antimicrobial Stewardship, including Quality of Care: Global Stewardship
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- SATURDAY – 569: Pathogen Type and Inappropriate Empiric Therapy (Iet) in Culture-Positive Skin and Soft Tissue Infection among Hospitalized Patients in the U.S., 2015-2017
Nabriva Therapeutics:
- SATURDAY – 573: Correlation of High-Risk Antibiotic Use and Hospital-Associated C. Difficile Infections: Data from 195 Us Hospitals
Session 235: AAR08 – New Antimicrobial Agents and New Research Technologies: Peptide and Glycopeptide Antimicrobial Agents
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Spero Therapeutics:
- SATURDAY – 594: A Pharmacokinetics-Pharmacodynamic Evaluation of the Novel Antibiotic Potentiator, Spr741, in Combination with Piperacillin/Tazobactam against Enterobacteriaceae
Session 236: AAR09 – Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents between Phase 2 and FDA Approval
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Motif Bio:
- SATURDAY – 640 – An Analysis of Pooled Efficacy Data from Two Phase 3 Trials of Iclaprim Compared to Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- SATURDAY – 641 – A Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Multicenter Studies to Evaluate the Safety of Intravenous Iclaprim versus Vancomycin
Nabriva Therapeutics:
- SATURDAY – 624: Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus Influenzae Using A One-Compartment In Vitro Infection Model
- SATURDAY – 643: In Vitro Activity of Lefamulin against Bacterial Pathogens Commonly Causing Acute Bacterial Skin and Skin Structure Infections (Absssi) and Bloodstream Infections (Bsi): Global Sentry Surveillance 2016
- SATURDAY – 644: In Vitro Activity of Lefamulin against Bacterial Pathogens Collected from Patients with Community-Acquired Respiratory Tract Infections (Carti) – Global Sentry Surveillance 2016
Paratek Pharmaceuticals:
- SATURDAY – 624: Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus Influenzae Using A One-Compartment In Vitro Infection Model
- SATURDAY – 625: Pharmacokinetic-Pharmacodynamic (Pk-Pd) Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (Cabp) for Streptococcus Pneumoniae (Sp) and Haemophilus Influenzae (Hi)
- SATURDAY – 626: In Vitro Activity of Omadacycline against Chlamydia Pneumoniae
- SATURDAY – 627: Omadacycline In VitroActivity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the U.S. and Europe During the Sentry Surveillance Program (2017)
- SATURDAY – 628: Population Pharmacokinetic (Pk) Analyses of Omadacycline Using Phase 1 and Phase 3 Data
Zavante Therapeutics:
- SATURDAY – 632: Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the Sentry Antimicrobial Surveillance Program
- SATURDAY – 633: Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in A Phase 3 Complicated Urinary Tract Infection Trial (Zeus)
- SATURDAY – 635: Fosfomycin (Fos) Activity against Carbapenem-Resistant Enterobacteriaceae (Cre) Clin. Isolates with Diverse Resistance (R) Mechanisms
- SATURDAY – 637: Molecular Characterization of Clin. Trial Isolates Exhibiting Increased Mic Results During Fosfomycin Treatment in A Phase 2/3 Clin. Trial for Urinary Tract Infections (Zeus)
- SATURDAY – 639: Evaluation of In Vitro Activity of Fosfomycin Alone and in Combination with Other Agents against Highly Resistant Pseudomonas Aeruginosa Clin. Isolates
Session 239: 239 – CIV01 – Clinical Studies of Adult Infectious Diseases: Staphylococcal and Other Gram-positive Infections
Time: 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Paratek Pharmaceuticals:
- SATURDAY – 701: Efficacy of Omadacycline and Linezolid against Characterized Drug Resistant S. Aureus from Combined Phase 3 Absssi Studies
Session 313: New Antibacterial Drugs, New Inhibitors: What, When, How
Time: 1:30 p.m. – 4:00 p.m.
Location: A410
Melinta Therapeutics:
3:00 p.m. – 3:30p p.m.
- 7 – Molecular Properties Matter: The Chemical Features and Resultant Biol. Profile of Delafloxacin
Sunday, June 10th
Session 384: SUNDAY – HMB Late-breakers
Time: 12:45 p.m. – 2:45 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
ContraFect:
- SUNDAY – HMB LB14 – Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum
Session 394: SUNDAY – CPHM Late-breakers
Time: 12:45 p.m. – 2:45 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- SUNDAY – CPHM LB2: Delafloxacin: Activity against Fastidious Organisms Tested by EUCAST vs CLSI Methodology
T2 Biosystems:
- SUNDAY – CPHM LB5: Validation of a Rapid Diagnostic Test Directly on Whole Blood for Detection of Blood Stream Infection
Session 403: SUNDAY – AAR Late-breakers
Time: 12:45 p.m. – 2:45 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
ContraFect:
- SUNDAY – AAR LB5 – Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans
Session 404: AAR01 – Surveillance of AMR: Molecular Typing, Clinical & Molecular Epidemiology: Global Surveillance Studies
Time: 12:45 p.m. – 2:45 p.m.
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- SUNDAY – 397: In Vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus Pneumonia (2014-207): Results from the Sentry Antimicrobial Surveillance Program
Session 410: AAR08 – New Antimicrobial Agents and New Research Technologies: Bacteriophage-Related Tools and Therapy
Time: 12:45 p.m. – 2:45 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
ContraFect:
- SUNDAY – 530 – CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals
- SUNDAY – 535 – Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)
- SUNDAY – 536 – Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis
Session 411: AAR08 – New Antimicrobial Agents and New Research Technologies: New Agents or Combinations that Inhibit Mycobacteria
Time: 12:45 p.m. – 2:45 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Spero Therapeutics:
- SUNDAY – 538: In Vitro Characterization of A Novel Gyrase Inhibitor (Spr719) against Nontuberculous Mycobacteria
- SUNDAY – 539: Potent Activity of A Novel Gyrase Inhibitor (Spr719/Spr720) In Vitro And in A Prolonged Acute Mycobacterium Abscessus Mouse Model of Infection
- SUNDAY – 540: Treatment of Mycobacterium Avium Subspecies Hominissuis (Mah) Infection with A Novel Gyrase Inhibitor (Spr719/Spr720) Was Associated with A Significant Decrease in Bacterial Load As Assessed in Macrophages, Biofilm and in Mice
Session 412: AAR08 – New Antimicrobial Agents and New Research Technologies: New Cephalosporins, Penems, and Carbapenems
Time: 12:45 p.m. – 2:45 p.m.
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Iterum Therapeutics:
- SUNDAY – 568: In Vitro Activity of Sulopenem, An Oral Penem, against Escherichia coli Isolated from Urine Specimens of Patients Across Canada in 2014-2016
- SUNDAY – 569: Sulopenem Activity Against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection
- SUNDAY – 570: Prediction of Sulopenem Activity against Enterobacteriaceae Using Ertapenem As A Surrogate
Spero Therapeutics:
- SUNDAY – 556: In Vitro Activity of Tebipenem (Spr859) against Penicillin-Binding Proteins of Gram-Negative Bacteria
- SUNDAY – 557: Characterization of the Mechanism of Action of Tebipenem (Spr859) in the Escherichia coli Macromolecular Synthesis Assay
- SUNDAY – 558: Antimicrobial Activity of Tebipenem (Spr859) against A Global Challenge Set of Enterobacteriaceae Isolates
- SUNDAY – 559: In Vitro Activity of Tebipenem (Spr859), Tebipenem-Pivoxil (Spr994) and Meropenem against A Broad Spectrum of Anaerobic Bacteria
- SUNDAY – 560: Antimicrobial Activity Assessment of Tebipenem (Spr859) against An Isolate Collection Causing Urinary Tract Infections
- SUNDAY – 561: In Vitro Bactericidal Activity and Post-Antibiotic Effect of Tebipenem (SPR859) against Susceptible and Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae as Compared to Levofloxacin (LVX) and Meropenem (MEM)
- SUNDAY – 562: The Impact of Varied Test Conditions on the In Vitro Activity of Tebipenem (Spr859) and Meropenem against Urinary Pathogens, Including Those Expressing Extended-Spectrum Beta-Lactamases (Esbl)
- SUNDAY – 563: Frequency of Spontaneous Mutations Conferring Reduced Susceptibility to Tebipenem (Spr859) among Susceptible and Extended-Spectrum Beta-Lactamase Producing Escherichia coli and Klebsiella Pneumoniae
- SUNDAY – 564: Dose Ranging and Dose Fractionation of Tebipenem-Pivoxil (Spr994) in Neutropenic Murine Thigh Models of Gram-Negative Bacterial Infection
- SUNDAY – 565: In Vivo Characterization of Tebipenem-Pivoxil (Spr994) in A Murine Ascending Escherichia coli Urinary Tract Infection Model
- SUNDAY – 566 – In Vivo Efficacy of Tebipenem-Pivoxil (Spr994) in An Acute Murine Thigh Infection Caused by Escherichia coli And Klebsiella Pneumoniae
- SUNDAY – 567 – In Vivo Efficacy of Tebipenem-Pivoxil (Spr994) in Neutropenic Murine Lung Models of Gram-Negative Bacterial Infection
Session 417: CIV01 – Clinical Studies of Adult Infectious Diseases: Respiratory Tract Infections
Time: 12:45 p.m. – 2:45 p.m.
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Nabriva Therapeutics:
- SUNDAY – 682: Lefamulin is Non-Inferior to Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia (Cabp): the Phase 3 Lefamulin Evaluation against Pneumonia (Leap 1) Study
- SUNDAY – 683: Lefamulin Demonstrates Favorable Safety and Tolerability in Adults with Community-Acquired Bacterial Pneumonia (Cabp) in the Phase 3 Lefamulin Evaluation against Pneumonia (Leap 1) Study
Session 420 – CIV02 – Infection Prevention and Control: Drug-Resistant Pathogens in Hospitals
Time: 12:45 p.m. – 2:45 p.m.
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Melinta Therapeutics:
- SUNDAY – 705: Predicting Carbapenem Resistance among Gram-Negative Pathogens in Complicated Urinary Tract Infections
- SUNDAY – 710: Budget Impact and Cost-effectiveness of Meropenem-vaborbactam (M-V) Compared with Ceftazidime-avibactam (C-A) in US Hospitals
Session 495: The Clinical Microbiology Laboratory of the Future (Organized in Cooperation with ESCMID and AMMI Canada)
Time: 3:00 p.m. – 5:30 p.m.
Location: A315-A316
T2 Biosystems:
4:15 p.m. – 4:30 p.m.
- 5 – Combined T2candida and Blood Culture Results Predict Mortality among Patients with Candidemia